- Home
- Center Of Excellence
- mCRPC Treatment
Centers of Excellence
The Latest Research on mCRPC Treatment
A single source educational forum with lectures, literature and conference information
From the Editor
Good Abi, Bad Abi - Charles Ryan
Hormonal signaling is an intriguing process with a lot of redundancy, promiscuity and feedback. Androgen metabolism is particularly complicated and likely reflects the absolute necessity of intact hormonal signaling for mammalian evolution. I have spent over 15 years studying many aspects of prostate cancer but probably the two most prominent facets of my research life relate to the development of treatments like abiraterone for mCRPC but also the study of the measure of hormones, their signaling patterns and its relationship to outcome in CRPC.
Charles J. Ryan, MD
Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.
Conference Highlights
Recent data from conferences worldwide
ASCO 2018 Prostate Cancer
- ASCO 2018: Treatment of Metastatic Hormone-Sensitive Prostate Cancer and Implications for Subsequent Management June 20, 2018
- ASCO 2018: Sipuleucel-T OS and Clinical Outcomes by Baseline PSA Quartiles in Patients with mCRPC: PROCEED Registry June 4, 2018
AUA 2018 Prostate Cancer
- AUA 2018: Association of Dose Reduction of Abiraterone Acetate plus Prednisone or Enzalutamide and PSA Progression in Veterans with mCRPC May 25, 2018
- AUA 2018: Interim Analysis of an Open Label Phase II Study of Enzalutamide and Radium-233 in Symptomatic, mCRPC May 23, 2018
- AUA 2018: Health-Related Quality of Life in Patients with mCRPC Treated with Cabazitaxel, CAPRISTANA May 19, 2018
- AUA 2018: The Impact of Prior Local Therapy on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer: Results from SEARCH May 19, 2018
EAU 2018 Prostate Cancer
- EAU 2018: Patient-Reported Outcome Measures in Men with Non-Metastatic Castration-Resistant Prostate Cancer: Baseline Data from the PROSPER Trial March 19, 2018
- EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial March 18, 2018
- EAU 2018: Prostate Cancer: Immediate and Late Complications - Robotic March 18, 2018
- EAU 2018: Prostate Cancer: Immediate and Late Complications - Open March 18, 2018
- EAU 2018: mCRPC New Drugs and Sequencing March 18, 2018
- EAU 2018: Prostate-Specific Antigen Response in Men with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: Results from PROSPER March 18, 2018
- EAU 2018: Using Clues from Studies of Genomic Evolution to Develop Clinically Applicable Biomarkers March 18, 2018
- EAU 2018: Local Control is Needed March 18, 2018
- EAU 2018: Systemic Therapy is the Standard of Care March 18, 2018
- EAU 2018: Clinical Data and Imaging are Doing the Job March 18, 2018
- EAU 2018: Clinical Data and Imaging are Doing the Job March 18, 2018
- EAU 2018: Genomic Screening Should Be Done March 18, 2018
- EAU 2018: Local and Metastasis Imaging Targeted Treatments are Needed March 18, 2018
ASCO GU 2018 Prostate Cancer
- ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone February 9, 2018
- ASCO GU 2018: Impact Of Statins On Outcomes In Patients With mCRPC: COU-AA-301 and COU-AA-302 Trials. February 9, 2018
- ASCO GU 2018: Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC February 9, 2018
SUO 2017 - Prostate Cancer
- SUO 2017: Contemporary Trends in Abiraterone and Enzalutamide Prescription by Provider Specialty December 4, 2017
- SUO 2017: Optimal Management of Castrate Sensitive M1 PCA December 4, 2017
- SUO 2017: Healthcare Resource Utilization, Costs And Treatments In A US Population Of Non-metastatic And Metastatic Castration Resistant Prostate Cancer December 3, 2017
SIU 2017 Prostate Cancer
- SIU 2017: Clinical Activity of Abiraterone Acetate in Docetaxel-Naïve and Docetaxel-Pretreated Asian Patients with Metastatic Castration Resistant Prostate Cancer October 25, 2017
- SIU 2017: Non-Androgen-Receptor-Targeted Options for mCRPC October 23, 2017
ESMO 2017 Prostate Cancer
- ESMO 2017: Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) September 10, 2017
- ESMO 2017: Abiraterone acetate + Prednisolone for metastatic Castration-Resistant Prostate Cancer (mCRPC) with early progression or non-response to Androgen Deprivation Therapy September 10, 2017
- ESMO 2017: Benefits of Abiraterone Acetate Plus Prednisone When Added to Androgen Deprivation Therapy in LATITUDE on Patient Reported Outcomes September 9, 2017
CUA 2017
- CUA 2017: Population-Based Analysis of Treatment Toxicity Among Men with Castration-Resistant Prostate Cancer (mCRPC). June 26, 2017
- CUA 2017: Fatigue in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide: Data from Randomized Clinical Trials. June 26, 2017
- CUA 2017: Impact of Abiraterone Acetate in Post-Docetaxel Setting on the Survival of Metastatic Castration-Resistant Prostate Cancer Patients: A Population-Based Study in Quebec June 26, 2017
- CUA 2017: Liquid Biopsy in Personalizing CRPC Therapy. June 24, 2017
TAT-10
- TAT-10: Development of Effective Chelators for Th227 to be Used in Targeted Thorium Conjugates June 21, 2017
- TAT-10: Radium-223 in Asymptomatic Metastatic Castration Resistance Prostate Cancer Patients Treated in an International Early Access Program (iEAP) June 21, 2017
- TAT-10: Ac225-PSMA-617: PSMA Targeting Alpha-Radiation Therapy of Patients with mCRPC June 21, 2017
ASCO 2017 Prostate Cancer
- ASCO 2017: Have Decisions by the National Institute for Health and Care Excellence Affected Outcomes of British Patients With Metastatic Castration-Resistant Prostate Cancer? June 6, 2017
- ASCO 2017: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer June 6, 2017
- ASCO 2017: PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration June 6, 2017
- ASCO 2017: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer June 6, 2017
- ASCO 2017: Targeting the AR: Biomarkers and Novel Therapeutic Approaches June 6, 2017
- ASCO 2017: Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis June 6, 2017
- ASCO 2017: Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial. June 6, 2017
- ASCO 2017: Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer June 6, 2017
- ASCO 2017: A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC) June 6, 2017
- ASCO 2017: Avelumab in metastatic castration-resistant prostate cancer (mCRPC) June 6, 2017
- ASCO 2017: Assessment of quality of life, cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC) June 6, 2017
- ASCO 2017: Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC) June 6, 2017
- ASCO 2017: Emerging Biomarkers of Chemotherapy Resistance June 6, 2017
- ASCO 2017: Clinical Implications of Genomic Sequencing in Prostate Cancer June 6, 2017
- ASCO 2017: Serum androgens and survival in metastatic castration resistant prostate cancer patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance) June 6, 2017
- ASCO 2017: Association of loss of tumor suppressor ZFP36 with lethal prostate cancer June 6, 2017
- ASCO 2017: Whole blood androgen receptor variant expression and overall survival in metastatic castrate resistant prostate cancer June 6, 2017
- ASCO 2017: The plasma lipidome in castration-resistant prostate cancer June 6, 2017
- ASCO 2017: Circulating tumour cells and survival in abiraterone and enzalutamide treated patients with castration-resistant prostate cancer June 6, 2017
- ASCO 2017: Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel in metastatic castration resistant prostate cancer June 6, 2017
- ASCO 2017: The aggressive variant prostate carcinoma molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer June 6, 2017
- ASCO 2017: Identification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC June 6, 2017
- ASCO 2017: Baseline CTC subtype to predict outcomes on mCRPC patients receiving enzalutamide compared to abiraterone June 6, 2017
- ASCO 2017: Clinical outcome of metastatic castration-resistant prostate cancer patients with a post-treatment circulating tumor cell of 0 vs CTC > 0: Post hoc analysis of COU-AA-301. June 6, 2017
- ASCO 2017: Challenges in Translating Molecular Results Into Meaningful Clinical Use June 5, 2017
- ASCO 2017: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer June 5, 2017
- ASCO 2017: Adding abiraterone for men with high-risk prostate cancer starting long-term androgen deprivation therapy: Survival results from STAMPEDE June 3, 2017
- ASCO 2017: A randomized phase II cross-over study of abiraterone + prednisone vs enzalutamide for patients with metastatic, castration-resistant prostate cancer June 3, 2017
- ASCO 2017: Targeting DNA Repair Mutations in Metastatic Castration-Resistant Prostate Cancer June 3, 2017
- ASCO 2017: Stereotactic Body Radiation: What Is Its Role in Advanced Disease? June 3, 2017
- ASCO 2017: Chemotherapy for Metastatic Castration-Resistant Prostate Cancer: Which Patient? Which Time? June 3, 2017
AUA 2016 Prostate cancer
ASCO GU 2016 Prostate Cancer
- ASCO GU 2016 More CNS Events With Enzalutamide Vs. Bicalutamide Treatment of mCRPC - Session Highlights January 18, 2016
- ASCO GU 2016 Large Study Reveals Significant Glucocorticoid Use in Both Treated and Untreated Prostate Cancer Patients - Session Highlights (Updated) January 18, 2016
ASCO GU 2016 mCRPC Treatment
- ASCO GU 2016 Among Treated Men with mCRPC, Researchers Find More Gaps in Refills with Enzalutamide Than Abiraterone - Session Highlights (Updated) January 18, 2016
- ASCO GU 2016 Clinicians’ attitudes and preferences in choosing the first line drug for mCRPC: Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) January 18, 2016
Abstracts
Editor selected abstracts and commentaries
- European Commission Approves Abiraterone Acetate + Prednisone for Early Stage Prostate Cancer
- EAU PCa 17: Hormone-naïve metastatic disease: How to treat it?
- EAU PCa 17: Castration resistant prostate cancer: Drug selection and treatment sequencing
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- CARG tool’s ability to predict older prostate cancer patients’ risk of toxicity: Beyond the Abstract
- Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
- Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
- A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.